GlassScriptPhysician profile
Leslie N Brown
NPI 1760790612
$4,060.19
in general payments reported to CMS, 2019-2025
19 companies · $29.09 in 2025
The $29.09 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,228 · 2022: $1,380 · 2023: $1,396 · 2024: $26.49 · 2025: $29.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,061.14 | 2021-2023 | Xifaxan, Trulance |
| Abbvie INC. | $989.66 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $409.86 | 2021-2023 | Entyvio |
| Celgene Corporation | $379.28 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $219.43 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $172.59 | 2021-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $135.51 | 2021-2023 | |
| Ardelyx, INC. | $125.84 | 2022-2023 | Ibsrela |
| Janssen Biotech, INC. | $122.10 | 2021-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $91.94 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $83.98 | 2021-2023 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $50.04 | 2023 | Givlaari |
| Genzyme Corporation | $44.83 | 2023 | |
| Pfizer INC. | $41.62 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.46 | 2023 | Cyltezo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $34.92 | 2021-2022 | |
| Novo Nordisk INC | $29.09 | 2025 | Wegovy |
| Alfasigma USA, INC. | $19.32 | 2021 | |
| Bausch & Lomb Americas INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.